The novel joint venture focuses on fundamental breakthrough treatments through first systemic application of promising CRISPR-Cas9 gene editing technology. Bayer is investing USD 335 million in a long-term alliance with CRISPR Therapeutics through new Bayer LifeScience Center unit. The joint venture will combine two leading knowledge areas: CRISPR-Cas9 from CRISPR Therapeutics as well as protein engineering and disease know-how by Bayer…
Source: Bayer